1. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA,
Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner
H, Wolf M. Fibroblast growth factor 23 and mortality
among patients undergoing hemodialysis. N Engl J Med
2008; 359:584-92.
2. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23
in chronic kidney disease.Kidney Int Suppl 2009;114:S34-
42.
3. Damasiewicz MJ, Toussaint ND, Polkinghorne KR.
Fibroblast growth factor 23 in chronic kidney disease: New
insights and clinical implications. Nephrology (Carlton)
2011;16:261-8.
4. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith
K, Collerone G, Sarwar A, Hoffmann U, Coglianese E,
Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast
Growth Factor-23 and left ventricular hypertrophy in
chronic kidney disease. Circulation 2009;119:2545-52.
5. Jongbloed F, Galassi A, Cozzolino M, Zietse R, Chiarelli
G, Cusi D, Brancaccio D, Gallieni M. Clinical significance
of FGF-23 measurement in dialysis patients. Clin Nephrol
2011;76:201-9.
6. Huang CL. Regulation of ion channels by secreted Klotho:
Mechanisms and implications. Kidney Int 2010;77:855-60.
7. Cozzolino M, Galassi A, Apetrii M, Covic A. What would
we like to know, and what do we not know about fibroblast
growth factor 23. J Nephrol 2011;24:696-706.
8. Choi BH, Kim CG, Lim Y, Lee YH, Shin SY. Transcriptional
activation of the human Klotho gene by epidermal growth
factor in HEK293 cells; role of Egr-1. Gene 2010;450:121-
7.
9. Adijiang A, Niwa T. An oral sorbent, AST-120, increases
Klotho expression and inhibits cell senescence in the kidney
of uremic rats. Am J Nephrol 2010;31:160-4.
10. Torres PU, Prié D, Molina-Blétry V, Beck L, Silve C,
Friedlander G. Klotho: An antiaging protein involved in
mineral and vitamin D metabolism. Kidney Int 2007;71:730-
7.
11. Bostrom MA, Hicks PJ, Lu L, Langefeld CD, Freedman
BI, Bowden DW. Association of polymorphisms in the
klotho gene with severity of non-diabetic ESRD in African
Americans. Nephrol Dial Transplant 2010;25:3348-55.
12. Oguro R, Kamide K, Kokubo Y, Shimaoka I, Congrains
A, Horio T, Hanada H, Ohishi M, Katsuya T, Okamura
T, Miyata T, Kawano Y, Rakugi H. Association of carotid
atherosclerosis with genetic polymorphisms of the klotho
gene in patients with hypertension. Geriatr Gerontol Int
2010;10:311-8.
13. Shimoyama Y, Taki K, Mitsuda Y, Tsuruta Y, Hamajima
N, Niwa T. KLOTHO gene polymorphisms G-395A
and C1818T are associated with low-density lipoprotein
cholesterol and uric acid in Japanese hemodialysis patients.
Am J Nephrol 2009;30:383-8.14. Kim Y, Jeong SJ, Lee HS, Kim EJ, Song YR, Kim SG, Oh
JE, Lee YK, Seo JW, Yoon JW, Koo JR, Kim HJ, Noh JW,
Park SH. Polymorphism in the promoter region of the
klotho gene (G-395A) is associated with early dysfunction
in vascular access in hemodialysis patients. Korean J Intern
Med 2008;23:201-7.
15. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux
C, Mayor B, Chazot C. Peripheral vascular calcification in
long-haemodialysis patients: Associated factors and survival
consequences. Nephrol Dial Transplant 2009;24:948-55.
16. Viaene L, Bammens B, Meijers BK, Vanrenterghem Y,
Vanderschueren D, Evenepoel P. Residual renal function
is an independent determinant of serum FGF-23 levels in
dialysis patients. Nephrol Dial Transplant 2012;27:2017-22.
17. Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-
Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P. The
influence of glomerular filtration rate and age on fibroblast
growth factor 23 serum levels in pediatric chronic kidney
disease. J Clin Endocrinol Metab 2010;95:1741-8.
18. Trombetti A, Richert L, Hadaya K, Graf JD, Herrmann FR,
Ferrari SL, Martin PY, Rizzoli R. Early post-transplantation
hypophosphatemia is associated with elevated FGF-23
levels. Eur J Endocrinol 2011;164:839-47.
19. Milinković NLj, Majkić-Singh NT, Mirković DD, Beletić
AD, Pejanović SD, Vujanić ST. Relation between 25(OH)-
vitamin D deficiency and markers of bone formation and
resorption in haemodialysis patients. Clin Lab 2009;55:333-
9.
20. Kurnatowska I, Grzelak P, Kaczmarska M, Stefańczyk
L, Nowicki M. Serum osteoprotegerin is a predictor of
progression of atherosclerosis and coronary calcification in
hemodialysis patients. Nephron Clin Pract 2011;117:297-
304.
21. Mesquita M, Demulder A, Wolff F, Mélot C, Damry N,
Dratwa M, Bergmann P. Osteoprotegerin and progression
of coronary and aortic calcifications in chronic kidney
disease. Transplant Proc 2010;42:3444-9.
22. Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K,
Ishimura E, Shimizu M, Miki T, Kim M, Nishizawa Y.
Clinical usefulness of the serum N-terminal propeptide
of type I collagen as a marker of bone formation in
hemodialysis patients. Am J Kidney Dis 2002;40:802-9.
23. Inaba M, Okuno S, Nagasue K, Otoshi T, Kurioka Y,
Maekawa K, Kumeda Y, Imanishi Y, Ishimura E, Ohta
T, Morii H, Kim M, Nishizawa Y. Impaired secretion of
parathyroid hormone is coherent to diabetic hemodialyzed
patients. Am J Kidney Dis 2001;38:139-42.
24. Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW,
Wanner C, Ketteler M, Boeschoten EW, Brandenburg
V; NECOSAD Study Group. Bone alkaline phosphatase
and mortality in dialysis patients. Clin J Am Soc Nephrol
2011;6:1752-9.25. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin
D3 supports osteoclastogenesis via functional vitamin D
response element of human RANKL gene promoter. J Cell
Biochem 2003;89:771-7.
26. Johnson DW, McIntyre HD, Brown A, Freeman J, Rigby RJ.
The role of DEXA bone densitometry in evaluating renal
osteodystrophy in continuous ambulatory peritoneal dialysis
patients. Perit Dial Int 1996;16:34-40.
27. Baszko-Blaszyk D, Grzegorzewska AE, Horst-Sikorska W,
Sowinski J. Bone mass in chronic renal insufficiency patients
treated with continuous ambulatory peritoneal dialysis. Adv
Perit Dial 2001;17:109-13.
28. Pasadakis P, Thodis E, Manavis J, Mourvati E, Panagoutsos
S, Vargemezis V. The identification of bone mineral density
in CAPD in comparison with HD patients. Adv Perit Dial
1995;12:247-53.
29. Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann
P, Mayer G. A comparison of quantitative computed
tomography and dual x-ray absorptiometry for evaluation
of bone mineral density in patients on chronic hemodialysis.
Am J Kidney Dis 2001;37:1247-52.
30. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G.
Fracture and bone mineral density in hemodialysis patients.
Clin Nephrol 2000;54:218-26.
31. Taal MW, Masud T, Gren D, Cassidy MJ. Risk factors for
reduced bone density in hemodialysis patients. Nephrol Dial
Transplant 1999;14:1922-8.
32. Ureña P, Bernard-Poenaru O, Ostertag A, Baudoin
C, Cohen-Solal M, Cantor T, de Vernejoul MC. Bone
mineral density, biochemical markers and skeletal fractures
in haemodialysis patients. Nephrol Dial Transplant
2003;18:2325-31.
33. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura
A, Inoue T. Risk factors for vertebral fractures in renal
osteodystrophy. Am J Kidney Dis 1999;33:287-93.
34. Ersoy FF, Passadakis SP, Tam P, Memmos ED, Katopodis
PK, Ozener C, Akçiçek F, Camsari T, Ateş K, Ataman
R, Vlachojannis JG, Dombros AN, Utaş C, Akpolat T,
Bozfakioğlu S, Wu G, Karayaylali I, Arinsoy T, Stathakis
PC, Yavuz M, Tsakiris JD, Dimitriades CA, Yilmaz ME,
Gültekin M, Karayalçin B, Yardimsever M, Oreopoulos
DG. Bone mineral density and its correlation with clinical
and laboratory factors in chronic peritoneal dialysis patients.
J Bone Miner Metab 2006;24:79-86.
35. Peter R. Ebeling. Approach to the patient with transplantation-
related bone loss. Journal of Clinical Endocrinology &
Metabolism 2009;94:1483-90.
36. Sprague SM, Josephson MA. Bone disease after kidney
transplantation. Semin Nephrol 2004;24:82-90.
37. Yu RW, Faull RJ, Coates PT, Coates PS. Calcium
supplements lower bone resorption after renal transplant.
Clin Transplant 2012;26:292-9.38. Sánchez González MC, Fernandez Giraldez E, Valdivielso
Revilla JM. Control of phosphorus and treatment with
vitamin D in chronic kidney disease prior to the start of
dialysis. Nefrologia 2008;28:39-45.
39. Stompór T. An overview of the pathophysiology of vascular
calcification in chronic kidney disease. Perit Dial Int
2007;27:215-22.
40. Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerström
G, Westin G, Larsson TE, Björklund P. Parathyroid Klotho
and FGF-receptor 1 expression decline with renal function
in hyperparathyroid patients with chronic kidney disease
and kidney transplant recipients. Kidney Int 2010;78:1024-
32. Epub 2010 Aug 4.
41. Komaba H, Koizumi M, Fukagawa M. Parathyroid
resistance to FGF23 in kidney transplant recipients: Back to
the past or ahead to the future? Kidney Int 2010;78:953-5.
42. Economidou D1, Dovas S, Papagianni A, Pateinakis
P, Memmos D. FGF-23 Levels before and after Renal
Transplantation. J Transplant 2009;2009:379082.
43. Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H,
Salusky IB. Mineral abnormalities and long-term graft
function in pediatric renal transplant recipients: A role for
FGF-23? Nephrol Dial Transplant 2011;26:3779-84.
44. Kanaan N, Claes K, Devogelaer JP, Vanderschueren D,
Depresseux G, Goffin E, Evenepoel P. Fibroblast growth
factor-23 and parathyroid hormone are associated with
post-transplant bone mineral density loss. Clin J Am Soc
Nephrol 2010;5:1887-92.
45. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang
MS, Lüthy R, Nguyen HQ , Wooden S, Bennett L, Boone
T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan
HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L,
Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van
G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin:
A novel secreted protein involved in the regulation of bone
density. Cell 1997;89:309-19.
46. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J,
Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle
WJ, Simonet WS. Osteoprotegerin-deficient mice develop
early onset osteoporosis and arterial calcification. Genes
Dev 1998;12:1260-8.
47. Hjelmesaeth J, Ueland T, Flyvbjerg A, Bollerslev J, Leivestad
T, Jenssen T, Hansen TK, Thiel S, Sagedal S, Røislien J,
Hartmann A. Early posttransplant serum osteoprotegerin
levels predict long-term (8-year) patient survival and
cardiovascular death in renal transplant patients. J Am Soc
Nephrol 2006;17:1746-54.
48. Bargnoux AS, Dupuy AM, Garrigue V, Jaussent I, Gahide
G, Badiou S, Szwarc I, Deleuze S, Vernhet H, Cristol JP,
Mourad G. Evolution of coronary artery calcifications
following kidney transplantation: Relationship with
osteoprotegerin levels. Am J Transplant 2009;9:2571-9.49. Malyszko J, Malyszko JS, Wolczynski S, Mysliwiec M.
Osteoprotegerin and its correlations with new markers of
bone formation and bone resorption in kidney transplant
recipients. Transplant Proc 2003;35:2227-9.
50. Bargnoux AS, Dupuy AM, Garrigue V, Deleuze S, Cristol JP,
Mourad G. Renal transplantation decreases osteoprotegerin
levels. Transplant Proc 2006;38:2317-8.
51. Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki
H, Moriguchi A, Nishizawa Y. Clinical evaluation of
the Elecsys beta-CrossLaps serum assay, a new assay for
degradation products of type I collagen C-tlopeptides. Clin
Chem 2001;47:1410-4.
52. Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y,
Imanishi Y, Yamakawa T, Ishimura E, Nishizawa Y. Serum
levels of TRAP5b, a new bone resorption marker unaffected
by renal dysfunction, as a useful marker of cortical bone loss
in hemodialysis patients. Calcif Tissue Int 2008;82:278-87.53. Marcén R, Ponte B, Rodríguez-Mendiola N, Fernández-
Rodriguez A, Galeano C, Villafruela JJ, Teruel JL, Burgos
FJ, Ortuño J. Vitamin D deficiency in kidney transplant
recipients: risk factors and effects of vitamin D3 supplements.
Transplant Proc 2009;41:2388-90.
54. Stein EM, Shane E. Vitamin D in organ transplantation.
Osteoporos Int 2011;22:2107-18.
55. Cunningham J. Pathogenesis and prevention of bone loss
in patients who have kidney disease and receive long-term
immunosuppression. J Am Soc Nephrol 2007;18:223-34.
56. Lim DS, Kee TY, Fook-Chong S, Zhang RF, Chandran
M. Prevalence and patterns of bone loss in the first
year after renal transplant in South East Asian patients.
Transplantation 2011;92:557-63.
Thank you for copying data from http://www.arastirmax.com
